Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity

Area of Science:

• Genetics
• Molecular Biology
• Cellular Biology

Background:

• Myotonic dystrophy (DM) is characterized by CTG trinucleotide repeat expansions in the DMPK gene.
• The p53 protein is a crucial cell-cycle checkpoint and DNA damage response regulator.
• The relationship between CTG repeat instability and the p53 pathway in DM remains unclear.

Purpose of the Study:

• To investigate whether the unstable CTG trinucleotide repeats in myotonic dystrophy (DM) are recognized as DNA damage by the p53 cell-cycle checkpoint system.
• To determine if p53 activation is altered in DM patients' tissues.

Main Methods:

• Assaying p53 mRNA and protein levels in muscle biopsies and fibroblast cell lines from DM patients and healthy controls.
• Comparing p53 levels between DM patients (varying expansion sizes) and controls.
• Treating cells with adriamycin to assess p53 response under induced DNA damage conditions.

Main Results:

• No significant differences in p53 mRNA or protein levels were observed between DM patients and controls, irrespective of CTG expansion size.
• Adriamycin treatment resulted in comparable p53 protein levels in both DM and control cells, indicating intact p53 response to external DNA damage.
• The CTG trinucleotide expansion itself did not appear to trigger the p53 surveillance system in adult tissues.

Conclusions:

• The CTG trinucleotide expansion in the myotonin gene does not activate the p53 surveillance system in adult tissues.
• The evasion of trinucleotide expansions from the p53-mediated DNA repair system may contribute to the observed genome instability in myotonic dystrophy.
• These findings suggest alternative mechanisms may be involved in the DNA repair and genome instability associated with DM.